The nominal deal value is $2.6B. The 174% premium is one of the largest ever for a biotech deal of this size.
Nestle already owned ~20% of AIMT based on investments dating back to 2016 and including, most recently, a $200M addition following FDA approval of Palforzia (#msg-153675586).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”